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Takayasu arteritis (TAK) is an autoimmune systemic vasculitis of unknown etiology. Although previous studies have revealed that HLA-
B*52:01 has an effect on TAK susceptibility, no other genetic determinants have been established so far. Here, we performed genome
scanning of 167 TAK cases and 663 healthy controls via Illumina Infinium Human Exome BeadChip arrays, followed by a replication
study consisting of 212 TAK cases and 1,322 controls. As a result, we found that the IL12B region on chromosome 5 (rs6871626, overall
p ¼ 1.7 3 1013, OR ¼ 1.75, 95% CI 1.42–2.16) and the MLX region on chromosome 17 (rs665268, overall p ¼ 5.2 3 107, OR ¼ 1.50,
95% CI 1.28–1.76) as well as the HLA-B region (rs9263739, a proxy of HLA-B*52:01, overall p ¼ 2.8 3 1021, OR ¼ 2.44, 95%
CI 2.03–2.93) exhibited significant associations. A significant synergistic effect of rs6871626 and rs9263739 was found with a relative
excess risk of 3.45, attributable proportion of 0.58, and synergy index of 3.24 (p% 0.00028) in addition to a suggestive synergistic effect
between rs665268 and rs926379 (p % 0.027). We also found that rs6871626 showed a significant association with clinical manifesta-
tions of TAK, including increased risk and severity of aortic regurgitation, a representative severe complication of TAK. Detection of these
susceptibility loci will provide new insights to the basic mechanisms of TAK pathogenesis. Our findings indicate that IL12B plays a
fundamental role on the pathophysiology of TAK in combination with HLA-B*52:01 and that common autoimmune mechanisms
underlie the pathology of TAK and other autoimmune disorders such as psoriasis and inflammatory bowel diseases in which IL12B is
involved as a genetic predisposing factor.Introduction
Takayasu arteritis (TAK [MIM 207600]) is an autoimmune
systemic vasculitis that was first reported from Japan.1 It
is estimated that TAK affects around 0.004% of the popula-
tion in Japan, especially young women aged between 15
and 35. Although TAK was originally thought to affect
individuals of mainly Asian origin, individuals with TAK
have been identified worldwide, though with lower preva-
lence compared to Asia.2 TAK is characterized by the
involvement of large arteries, especially the aorta and its
large branches, and is grouped into ‘‘vasculitis affecting
large vessels’’ according to the Chapel Hill classification.3
Individuals with TAK develop a wide range of symptoms
such as fatigue, syncope, and lowering of vision in addi-
tion to its characteristic complications including aortic
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The Amerpressure between right and left upper limbs. Previous
studies have revealed that genetic components are
involved in the pathogenesis of TAK, and HLA-B*52:01 is
so far the only established genetic factor across the
world.4–7 Other genetic components especially outside of
the HLA locus have not been confirmed to date. Establish-
ment of association with non-HLA regions would lead to a
deeper understanding of the basics of TAK pathology and
the development of a novel therapy for this vasculitis.
Here, we performed a genome-scanning study of TAK to
identify the genetic predisposing factors for TAK.
Subjects and Methods
Study Subjects
A total of 379 TAK cases and 1,985 controls were enrolled in this
study. All the cases were diagnosed based on the criteria of, Kyoto 606-8507, Japan; 2Department of Rheumatology and Clinical Immu-
; 3Department of Molecular Pathogenesis, Medical Research Institute, Tokyo
vascular Medicine, Graduate School of Medicine, The University of Tokyo,
ine, The University of Tokyo, Tokyo 113-8655, Japan; 6Department of Bio-
Dental University, Tokyo 113-8510, Japan; 7Department of Cardiovascular
rtment of Medicine and Clinical Science, Kyoto University Graduate School
555, Japan; 10Division of Clinical Nephrology and Rheumatology, Niigata
, Japan; 11Department of Cardiovascular Medicine, Kyoto University Grad-
Tokyo Women’s Medical University, Tokyo 162-0054, Japan; 13Department
06-8507, Japan; 14Jichi Medical University, Tochigi 329-0498, Japan
y of Human Genetics. All rights reserved.
ican Journal of Human Genetics 93, 289–297, August 8, 2013 289
Table 1. Summary of Study Subjects
Case Control
Genome Scanning
Number 167 663
Agea 45.7 5 15.2 53.5 5 13.5
Female ratio 0.92 0.74
Age at onseta 30.5 5 14.5 NA
Genotyping Illumina Infinium
Human-Exome
BeadChip
Illumina Infinium Human-
Exome BeadChip
Subjects with
clinical information
AR:87; CRP:89 NA
Institutions Kyoto University;
Tokyo Women’s
Medical University
Kyoto University
Replication Study
Number 212 1,322
Agea 46.6 5 17.6 53.3 5 13.4
Female ratio 0.94 0.62
Age at onseta 27.0 5 11.8 NA
Genotyping Taqman assay Illumina Infinium Human
Omni 2.5-4 BeadChip,
Illumina Infinium Human
Omni 2.5-8 BeadChip
Subjects with
clinical information
AR:102; CRP:None NA
Institutions Tokyo Medical and
Dental University;
Kyoto University;
Niigata University
Kyoto University
Abbreviations are as follows: NA, not applicable; AR, aortic regurgitation; CRP,
C-reactive protein.
aMean 5 standard deviation (SD).American College of Rheumatology8 or guideline provided by
Japanese Circulation Society.9 The control subjects were collected
as a part of the Nagahama Prospective Genome Cohort for
Comprehensive Human Bioscience (TheNagahama Study), a com-
munity-based prospective multiomics cohort study conducted by
Kyoto University.10 This study was approved by the local ethical
committees at each institution, and written informed consent
was obtained from each subject involved in the study.
Genome Scanning
Illumina Infinium Human Exome BeadChip arrays (Illumina)
were used for genome scanning of the cases and the controls.
The genome scanning was conducted in Center for Genomic
Medicine, Kyoto University Graduate School of Medicine.
Quality Control of Genome Scanning
Polymorphisms showing success rates less than 0.95 in either cases
or controls, departure from Hardy-Weinberg equilibrium (HWE)
(p < 1.0 3 105), or minor allele frequencies less than 0.05 in
both cases and controls were excluded from the analysis. Subjects
who showed success rates less than 0.95 or evidence of relatedness
with other subjects were also excluded. Kinship between study
subjects were estimated by PLINK.11 Quantile-quantile plot (QQ290 The American Journal of Human Genetics 93, 289–297, August 8plot) was used to assess the population stratification of the study.
Because 1,827 markers over 24,487 were located in the HLA locus
in which polymorphisms are very closely linked with each other,
the 22,660markers in the non-HLA regions were used for QQ plot.
Replication Study
TheSNPswithpvalues less than1.03105 in thegenomescanning
were selected for the replication study. Because the association
found in the HLA-B region (MIM 142830) was largely attributable
to HLA-B*52:01, rs9263739, a proxy of HLA-B*52:01, was selected
as a representative of the HLA locus. In the replication study, case
samples were genotyped by Taqman Assay (Applied Biosystems)
and control genotypes were extracted from array data (Table 1).
Combined Study and Association Study for Genotypes
Association studies of genotypes were performed by chi-square test
based on 2 3 2 contingency tables. Combined study of the two
studies was performed by inverse-variance method, assuming a
fixed-effects model from the effect size (logarithm of odds ratio
[OR]) in each study. A significant level for detecting susceptibility
genes was set as 2.0 3 106, which was obtained by Bonferroni’s
correction. A stringent cut-off level of 5.0 3 108 was also applied
to assess overall significance.
Imputation of Genotypes
Mach dat2 software12 was used for imputation of the whole
genomes based on the results of genome scans with the use of the
East Asian panel of HapMap phase II data as reference. SNPs with
low imputation scores (Rsq< 0.3) were excluded from the analysis.
Calculation of Linkage Disequilibrium
LD between SNPs in the Illumina Infinium Human Exome Bead-
Chip was assessed based on the genome-scanning data. HapMap
project phase II data was used when SNPs were not contained in
the array. LD between HLA-B*52:01 and SNPs was calculated by
combining our previous HLA-genotyping data of the 173 TAK
cases (C.T., unpublished data) by WAKFlow system (Wakunaga
Pharmaceutical) with the genome-scanning data.
Estimation of Interaction
We used the method for evaluation of interaction proposed by
Andersson et al.13 Gene-gene interaction was defined as departure
from additivity of two loci andmeasured by three indices based on
calculation of relative risk (RR); relative excess risk due to interac-
tion (RERI), attributable proportion (AP), and synergy index (SI).
We considered an interaction as significant only when both
RERI and AP were different from 0 and additionally SI was more
than 1. The very low prevalence of TAK justifies to approximate
OR by RR. For instance, when we assessed the interaction
between rs9263739 and rs6871626 through these three indices,
the subjects were classified into four groups: negative for both
rs9263739 T allele and rs6871626 A allele, positive for
rs9263739 T allele and negative for rs6871626 A allele, negative
for rs9263739 T allele and positive for rs6871626 A allele, and pos-
itive for both rs9263739 T allele and rs6871626 A allele. Logistic
models were used to calculate the indices.
In Silico Analysis of Association between the Gene
Expression and rs6871626
We used two methods to assess the effect of rs6871626 on the
IL12B (MIM 161561) expression. Gene expression data for IL12B, 2013
Figure 1. Manhattan Plot of Genome Scanning
The horizontal line indicates the significant level based on Bonfer-
roni’s correction. The HLA locus on chromosome 6 and the IL12B
region on chromosome 5 reached the significant level.in lymphoblastoid cells were obtained from GEO database (acces-
sion number GSE6536)14 and analyzed for association with
genotypes of rs6871626 obtained from HapMap project. Genevar
software was used for analyzing the IL12B expression in adipose
and skin in association with the rs6871626 genotypes.15 Associa-
tions between genotypes and gene expression were evaluated by
a linear regression analysis.
Associations between Genotypes and Clinical
Phenotypes of TAK
Data of age at onset were analyzed for the association with the
susceptibility alleles. AR, ischemic heart disease, and pulmonary
infarction were selected for the association with genotypes as
representative complications of TAK because cardiovascular event
was the major cause of death in TAK individuals16 and it was pre-
viously demonstrated that these phenotypes were associated with
HLA-B*52:01,17 suggesting that genetic backgrounds were at least
partly responsible for these clinical manifestations. Data of the
clinical manifestations were collected in Kyoto University Hospi-
tal or Tokyo Medical and Dental University by medical doctors
who were blinded to genotype data reviewing clinical charts.
Although AR evaluated by transthoracic echocardiography or
angiography was positive for 44% of cases, other complications
were found in less than 16%. Only AR was analyzed because of
lack of power for other manifestations. Data for severity of AR
assessed by the three categories18 (mild, moderate, and severe)
were also collected. C-reactive protein (CRP) was focused on as
a biomarker reflecting disease activity. We calculated time-aver-
aged CRP and dosage of prednisolone. Individuals who had
visited hospitals for less than 500 days were excluded from the
analysis of CRP. The associations between genotypes and clinical
phenotypes were assessed by logistic regression analysis for exis-
tence of AR or linear regression analysis for severity of AR, time-
averaged CRP, and age at onset. Time-averaged CRP was analyzed
in condition with time-averaged dosage of prednisolone alone or
in combination with rs3093059 genotypes in the CRP (MIM
123260) region. Associations between genotypes and clinical
manifestations with p values less than 0.05 were regarded as
significant.
Statistical Analysis
Statistical analyses were performed by PLINK v.1.07, R statistical
software, or SPSS v.18.0.The AmerResults
A summary of basic information of the subjects in our
study is shown in Table 1. DNA samples from 167 cases
and 663 healthy controls were genome scanned with the
use of Illumina Human-Exome arrays containing 247,730
SNPs. One sample of the TAK cases and six samples in con-
trols with success rates of less than 0.95 or with evidence of
relatedness with other subjects (PI_HAT> 0.2 calculated by
PLINK, see Subjects and Methods) were excluded from
further analysis. The genotyping revealed that more than
80% of the markers in the array were monomorphic and
9% of the markers showed low minor allele frequency
(<0.05) in the Japanese population, respectively. A total
of 24,487 markers remained after filtering of SNPs that
showed success rates of less than 0.95, deviation from
HWE (p < 1 3 105) in either cases or controls, or minor
allele frequencies of less than 0.05 in both cases and con-
trols. The mean success rate of individuals was 0.999 after
filtering.
Association studies were performed by chi-square test to
compare allele frequencies between cases and controls.
Population stratification was evaluated by QQ plot. The
results indicated a lambda value of 1.05 in the QQ plot,
indicating no excess population stratification in our study.
Manhattan plot revealed that a region on chromosome 5
as well as the HLA locus showed significant associations
that satisfied the genome-wide significant threshold
obtained by Bonferroni’s correction (p ¼ 2.0 3 106;
Figure 1). The associations were also confirmed by the
imputed results (Figure S1 available online). rs4947248 in
the HLA-B region, which is a known susceptibility
gene to TAK, showed the strongest association (p ¼ 5.1 3
109, OR ¼ 2.17, 95% CI 1.67–2.82). rs9263739, a proxy
of HLA-B*52:01 (r2 ¼ 0.94), similarly showed a significant
association (p ¼ 8.0 3 109, OR ¼ 2.30, 95% CI 1.72–
3.07; Table 2) and in moderate LD with rs4947248 (D’ ¼
0.95, r2 ¼ 0.58). Because rs4947248 did not show evidence
of an independent association from rs9263739 in logistic
regression analysis (p ¼ 0.04), we assumed that the top
association in the HLA locus was attributable to HLA-B*
52:01. rs6871626 in the IL12B region on chromosome 5
also showed a significant association (p ¼ 1.8 3 107,
OR ¼ 1.90, 95% CI 1.49–2.42; Table 2 and Figure 2A).
Four other loci showed suggestive associations in our study
(p < 5.0 3 105; Table 2). No departure from HWE was
observed for these six SNPs (pR 0.041).
A replication study was performed with the use of DNA
samples from 212 cases and 1,322 controls. The six SNPs
with p values less than 5.03 105 in the genome scanning
were genotyped in the replication study. rs9263739 was
selected as a representative of the associations in the HLA
locus. As a result, the significant associations of TAK with
rs6871626 and rs665268 in the MLX (MAX dimerization
protein [MIM 602976]) region on chromosome 17 as well
as rs9263739 were replicated (p ¼ 1.1 3 107, 0.0032,
and 6.0 3 1015, respectively; Table 2, Figures 2Aican Journal of Human Genetics 93, 289–297, August 8, 2013 291
Table 2. Results of Association Studies for TAK Susceptibility
SNP Chr Position Gene Ref(A1) Var(A2)a
Genome Scan Replication Meta-analysis
Case
A2freq
Cont
A2freq p
Case
A2freq
Cont
A2freq p p
OR (95%
CI)
rs10934853 3 129521063 EEFSEC A C 0.59 0.45 1.3 3 105 0.52 0.47 0.066 2.6 3 105 1.40
(1.20–1.64)
rs6871626 5 158759370 IL12B C A 0.53 0.37 1.8 3 107 0.53 0.39 1.1 3 107 1.7 3 1013 1.75
(1.42–2.16)
rs9263739 6 31219335 CCHCR1 C T 0.27 0.14 8.0 3 109 0.30 0.14 6.0 3 1015 2.8 3 1021 2.44
(2.03–2.93)
rs1570843 6 84577239 RIPPLY2 C T 0.62 0.50 4.6 3 105 0.54 0.51 0.19 3.1 3 104 1.34
(1.14–1.57)
rs12102203 15 49578851 DMXL2 G A 0.64 0.49 3.8 3 106 0.53 0.54 0.71 0.0081 1.24
(1.06–1.46)
rs665268 17 37975555 MLX A G 0.58 0.44 1.7 3 105 0.49 0.42 0.0032 5.2 3 107 1.50
(1.28–1.76)
Abbreviations are as follows: chr, chromosome; ref, reference allele; var, variant allele; CaseA2freq, variant allele frequency in cases; ContA2freq, variant allele
frequency in controls; OR, odds ratio; CI, confidence interval. Positions are according to National Center for Biotechnology Information (NCBI) build 36.
aRisk alleles for TAK based on the results of the genome scanning are set as variant alleles.and 2B). The suggestive association on chromosome 15
(Figures S1 and 1) was not replicated. Again, no departure
from HWE was observed (pR 0.11).
A combined study in which the associations in the two
studies were integrated by inverse-variance method
demonstrated that rs6871626, rs665268, and rs9263739
showed significant associations (p ¼ 1.7 3 1013, 5.2 3
107, and 2.8 3 1021; OR ¼ 1.75, 1.50, and 2.44; 95%
CI 1.42–2.16, 1.28–1.76, and 2.03–2.93, respectively; Table
2) satisfying the significance obtained by Bonferroni’s
correction. rs6871626 and rs9263739 satisfied the more
stringent, widely accepted genome-wide significance (p ¼
5.0 3 108).
Because it was suggested that genetic components had
influence on the manifestations of the disease,17 we
analyzed whether the variant of the IL12B region had clin-
ical effects on the disease course or severity. Age at onset
was not associated with rs6871626 (p ¼ 0.36), whereas a
significant association between rs6871626 and develop-
ment of AR was observed in a recessive model (p ¼
0.0046; Figure 3A). Focusing on the cases with AR, a signif-
icant association between rs6871626 and severity of AR
was observed in the recessive model (p ¼ 0.0018;
Figure 3B). Risk allele of rs6871626 (A allele) also demon-
strated a significant association with increased level of
time-averaged CRP, which was a representative marker of
the disease activity (p ¼ 0.021; Figure 3C). The association
between rs6871626 and CRP levels was independent from
rs3093059 in the CRP region (p ¼ 0.029), which showed
the strongest association with circulating CRP levels
in Japanese.19 These associations between rs6871626
and clinical manifestations were independent from
rs9263739 (conditioned p value of rs6871626 % 0.020).
Although rs665268 also demonstrated a significant associ-
ation with development of AR in a dominant model (p ¼
0.0089; Figure S2A), the association was not significant292 The American Journal of Human Genetics 93, 289–297, August 8in condition with rs9263739 (p ¼ 0.080). No significant
associations were observed between rs665268 and other
clinical phenotypes (Figures S2B and S2C).
Next, we investigated the interaction between the IL12B
and HLA-B loci to TAK susceptibility. The risk of TAK in the
population positive for both rs6871626 A allele and
rs9263739 T allele surpassed the product and sum of the
risk in those who were positive for either rs6871626 A
allele or rs9263739 T allele alone (Figure 4). The analysis
revealed that those who were positive for both had OR of
6.00 (95% CI 4.22–8.55), whereas those who were positive
for either rs9263739 T allele or rs6871626 A allele showed
OR of 1.80 (95% CI 1.11–2.93) or 1.74 (95% CI 1.23–2.47),
respectively. Interaction measures revealed RER of
3.46 (p ¼ 1.4 3 105, 95% CI 1.90–5.01), AP of 0.58
(p ¼ 1.0 3 1012, 95% CI 0.42–0.73), and SI of 3.24
(p ¼ 0.00028, 95% CI 1.72–6.11). This significant interac-
tion between IL12B and HLA-B on TAK susceptibility could
be observed in both studies (Table 3). The synergistic inter-
action effects between rs6871626 and rs9263739 were not
evident in the clinical manifestations associated with
rs6871626 (Figure S3). When we analyzed the interaction
between the MLX and HLA-B regions, we observed sugges-
tive interaction with RER of 1.73, AP of 0.43, and SI of 2.29
(p % 0.027; Figure S4 and Table S1). The associations
between the interaction and clinical manifestations were
not significant (Figure S5).
IL12B encodes a common subunit of the IL12 and IL23
protein, known as p40. Because previous studies showed
that the IL23R/IL12RB2 (MIM 607562/601642) region
was associated with Behc¸et disease20 (MIM 109650),
another connective tissue disease where vasculitis is
involved in its pathology, we investigated this region for
the possible associations in the current study. As a result,
no suggestive association was found, either in our study
or in the imputed results (Figure S6)., 2013
Figure 2. Associations of the IL12B and MLX Regions with the
Susceptibility to TAK
Associations of SNPs in the (A) IL12B and (B) MLX regions in the
genome scanning are plotted according to the position of the
markers. Red circles indicate results of the current genome scan-
ning. Blue circles indicate results of the imputation analysis based
on the current results. The middle panel indicates recombination
rates. The lower panel indicates LD of markers. Asterisk indicates a
recombination hot spot in the IL12B region.Discussion
This study provides a convincing evidence of associations
between non-HLA genes and TAK susceptibility along
with a synergistic role of susceptibility genes to TAK. The
lack of evidence for associations of non-HLA genes with
TAK so far is attributable to the lack of GWASs of TAK per-
formed to date. Low prevalence of this disease had made it
difficult to collect DNA samples to obtain sufficient power
todetect susceptibility genes andperformaGWAS.Previous
studies have revealed that the IL12B region was associated
with awide variety of autoimmune disorders and infectious
diseases, including psoriasis21–23 (MIM 177900), anky-
losing spondylitis24 (MIM 106300), Crohn disease25 (CD
[MIM 266600]), ulcerative colitis26 (UC [MIM 191390]),The Amerand leprosy27 (MIM 609888). rs6871626 showed a signifi-
cant association with UC and leprosy over the genome-
wide significance. Notably, rs6871626 A allele is susceptible
to UC but protective against leprosy. A previous study from
Turkey reported a suggestive association of TAK with
rs3212227 in the 30 UTR of the IL12B region.28 rs3212227
is not in strong LD with rs6871626 in the Japanese popu-
lation (r2 ¼ 0.11) and in Europeans (r2 ¼ 0.06) because
of a recombination hot spot adjacent to rs6871626
(Figure 2A). In fact, an imputed association of rs3212227
with TAK in the current study resulted in only a suggestive
association (p ¼ 0.0027). There is a possibility that
rs6871626 was responsible for the suggestive association
between rs3212227 and TAK reported in the Turkish popu-
lation. The association between gene expression and SNPs
in the IL12B region appears to be complicated and inconsis-
tent across different studies. rs3212227 in the 30 UTR and
rs17860508, an ins/del polymorphism in the promoter
region of IL12B, were shown to have potential effects on
the gene expression.29,30 However, the previous studies
showed that the association patterns varied according to
the cell type and the protocol used for stimulation.31–33
No previous report analyzed the effects of rs6871626 on
thegene expressionof IL12B. Althoughour in silico analysis
failed to show the effects of rs6871626 on IL12B expression
(data not shown, see Subjects and Methods), specific cell
types or stimulus could lead to a significant association.
Because a recent study showed that a haplotype of SNPs
in the IL12B region could influence the gene and protein
expression of IL12B,22 a combination of rs6871626 and
other SNPs in the IL12B region might lead to consistent
results.
The associations between rs6871626 and clinical mani-
festations of TAK suggest the fundamental effects of
IL-12p40 protein on TAK progression as well as TAK onset.
We found that HLA-B*52:01 was associated with AR as
reported previously (p ¼ 0.00014). This finding supported
the accuracy of our data. Although the risk allele of
rs6871626 was associated with a significant dose-depen-
dent increase in risk and severity of AR and in circulating
CRP levels (p ¼ 0.013, 0.030, and 0.023, respectively),
these associations were more evident in a recessive
manner. This raises a possibility that those who are homo-
zygous for rs6871626 have strong disease activity that
exceeds the additive disease activity of cases with single
risk alleles, leading to severe destruction of aortic valve.
Genetic variations in IL12B are known to influence the
risk of psoriasis21–23 and CD.25 Because ustekinumab, a
monoclonal antibody against IL-12p40, is an effective
treatment for both diseases,34,35 our findings would raise
a possibility of its therapeutic use for TAK by targeting
the IL-12/23 pathway. A previous study reported that the
level of IL-12 protein was increased in TAK cases compared
to healthy populations,36 whereas there have been no
reports addressing the circulating levels of IL-23 in TAK
cases. IL-12 directly leads to type 1 helper T cell prolif-
eration37 and IL-23 upregulates IL-17 production andican Journal of Human Genetics 93, 289–297, August 8, 2013 293
Figure 3. Associations between
rs6871626 Genotypes and Clinical
Manifestations of TAK
An association between rs6871626 geno-
types and (A) development of AR, (B)
severity of AR, and (C) time-averaged CRP
levels in TAK cases. The p value was calcu-
lated by (A) logistic regression analysis, (B)
linear regression analysis, and (C) linear
regression analysis with time-averaged
dosage of prednisolone as covariate. The
recessive model is applied to all calcula-
tions. Severity of 1 to 3 in AR corresponds
tomild,moderate, and severe, respectively.
Mean5 SD are indicated for (B) and (C).supports survival of activated Th17 cells.38 Further ana-
lyses addressing circulating T cells in individuals with
TAK or cell types infiltrating the artery specimen obtained
from cases would provide clues to specify a critical
pathway in TAK pathology.
The synergistic effect between rs6871626 and HLA-B*
52:01 was notable. Those carrying both risk alleles had
OR of 6.00 in comparison with those not carrying any
risk alleles. Combination of rs6871626 and HLA-B*52:01
showed tendency of severe clinical phenotypes. Thus, we
assume that increase of subjects and extraction of subjects
who are homozygous for rs6871626 and positive for HLA-
B*52:01 would provide evidence for significant effects of
the combination on the disease phenotypes. The syner-
gistic effect of these two loci raises a possibility that
immune-related cells that recognize a yet-to-be-deter-
mined antigen through HLA-B*52:01 can be overactivated
by IL-12/23 whose expression or function is modulated by
rs6871626. In vitro analysis of immune-related cells from
cases with TAK or healthy individuals would provide
functional evidence of this synergistic role in the TAK
pathogenesis.Figure 4. A Synergistic Effect between IL12B and HLA-B*52:01
on TAK Susceptibility
ORs are shown for the four strata of subjects according to
combination of rs6871626 and rs9263739 genotypes. Those who
are negative for rs9263739 T allele, a proxy of HLA-B*52:01,
and rs6871626 A allele are used as reference. ORs and 95% CI
are indicated.
294 The American Journal of Human Genetics 93, 289–297, August 8rs665268 is a missense mutation of MLX that alters
the 139th glutamine to arginine (Gln139Arg). MLX is a
member of the basic helix-loop-helix leucine zipper
(bHLH-Zip) transcription factor family and regulates gene
expression by forming heterodimers with Mad protein.39
The 17q21 region, whose associations with other autoim-
mune diseases including psoriasis40 and CD41 were shown,
contains a number of genes including immune-related
genes and polymorphisms that are in strong LD with
each other (Figure 2B), so the corresponding gene to TAK
susceptibility was inconclusive. Because risk allele fre-
quency of rs665268 is comparable to that of rs6871626,
the lack of associations between rs665268 and clinical
manifestations and the weaker interaction between
rs665268 and HLA-B*52:01 compared to rs6871626 might
be a reflection of the milder effect of rs665268 on TAK pro-
gression. No interaction was observed between rs665268
and rs6871626 (data not shown).
We set the relatively low cut-off value of imputation
score (Rsq R 0.3) in the imputation analysis to increase
sensitivity at the expense of specificity, but we failed to
find other candidates of susceptibility loci. Another impu-
tation analysis based on the data from the 1000 Genomes
Project42 revealed the same signals as the current study
(data not shown). However, because the array used in
the current study focused on SNPs in exons or nearby
genes, it did not fully cover the whole genome with dense
markers even in imputation analysis. There is a possibility
that other SNPs not tagged by the markers on the array
are associated with TAK. When the associations in the
HLA locus were conditioned by rs9263739 or rs4947248,
the most significantly associated SNPs, suggestive associa-
tion signals in this locus could still be observed (the small-
est p value ¼ 5.5 3 105, data not shown). The use of
arrays with denser markers especially in intergene
regions and using an increased number of cases could
lead to the discovery of other susceptibility regions or
independent associations in the HLA locus. Considering
that both of the non-HLA susceptibility loci to TAK
found in the current study are also associated with psori-
asis and inflammatory bowel diseases, further analysis of
TAK susceptibility genes would reveal other overlapping
loci and common autoimmune mechanisms between
TAK and other autoimmune diseases. It is feasible to, 2013
Table 3. Synergistic Effects between IL12B and HLA-B*52:01 in Each Study
Study
RERI AP SI
(95% CI) p (95% CI) p (95% CI) p
Genome scanning 2.90 (0.60–5.20) 0.014 0.50 (0.23–0.78) 0.00034 2.57 (1.08–6.09) 0.032
Replication study 3.87 (1.70–6.05) 0.00049 0.62 (0.42–0.81) 4.7 3 1010 3.76 (1.51–9.32) 0.0043
Combined study 3.46 (1.90–5.02) 1.4 3 105 0.58 (0.42–0.73) 1.0 3 1012 3.24 (1.72–6.11) 0.00028
Abbreviations are as follows: RERI, relative excess risk; AP, attributable proportion; SI, synergy index; CI, confidence interval.analyze whether these two loci are associated with
TAK and whether the interactions are observed in other
populations.
Taken together, the current study identified two suscep-
tibility genes to TAK and provided evidence of a common
immunological pathway exerted by the IL12B region that
is involved in the etiology of TAK and other autoimmune
disorders and of its synergistic role with HLA in the suscep-
tibility to TAK.Supplemental Data
Supplemental Data include six figures and one table and can be
found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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